HSCT provides effective treatment for lymphoproliferative disorders in children with primary immunodeficiency

In a national cohort, we demonstrate the safety and efficacy of tailored chemo-immunotherapy followed by RIC HSCT for PID-associated lymphoproliferative disorders in children.

https://www.jacionline.org/article/S0091-6749(20)30626-6/abstract?rss=yes

Source: Journal of Allergy and Clinical Immunology - May 2, 2020 Category: Allergy & Immunology Authors: Giulia Prunotto, Ugonna T. Offor, Sujith Samarasinghe, Robert Wynn, Ajay Vora, Ben Carpenter, Claire Gowdy, Kieran McHugh, Kevin P. Windebank, Attilio Maria Rovelli, Mary A. Slatter, Andrew R. Gennery, Paul Veys, Chris M. Bacon, Simon Bomken, Giovanna Luc Source Type: research

More News: Allergy | Allergy & Immunology | Children | Immunotherapy | Primary Immunodeficiency Disease